← Back to Search

Genomic Analysis for Cancer

N/A

Recruiting

Led By Shridar Ganesan

Research Sponsored by Rutgers, The State University of New Jersey

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Paraffin blocks of the patient's tumor tissue are available and accessible for analysis

Karnofsky/Lansky performance score >= 30

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 15 years

Awards & highlights

Study Summary

This triallooks into using genomic sequencing to diagnose and treat cancer, potentially improving care for patients with rare, hard-to-treat cancers.

Who is the study for?

This trial is for patients with rare or hard-to-treat cancers who have a Karnofsky/Lansky score of at least 30, indicating they can care for themselves. They must have confirmed cancer diagnosis, available tumor tissue samples, and consent to participate. Those with life expectancy under 3 months or very poor physical condition (score below 30) cannot join.Check my eligibility

What is being tested?

The study is examining the use of targeted genomic analysis on blood and tissue from cancer patients to identify genetic changes that could be important in cancer development. This may help improve diagnosis and treatment options for those with rare cancers that respond poorly to standard therapies.See study design

What are the potential side effects?

Since this trial involves collecting samples and analyzing them in a lab rather than testing drugs, there are no direct side effects related to medications. However, the procedure might cause discomfort or complications like bleeding or infection at the collection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My tumor tissue samples are available for testing.

Select...

I can care for myself but may need occasional help.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 15 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 15 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Frequencies of individual specific mutations and combinations of mutations of related pathway genes

Rate of actionable mutations in rare and/or poor prognosis cancers

Trial Design

1Treatment groups

Experimental Treatment

Group I: Ancillary-Correlative (genomic analysis)Experimental Treatment2 Interventions

Previously collected tissue samples are analyzed for the presence of mutations via next generation sequencing. Patients may also undergo collection of blood samples for analysis of circulating cell-free DNA and circulating tumor cells.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,672 Previous Clinical Trials

40,925,341 Total Patients Enrolled

Rutgers, The State University of New JerseyLead Sponsor

429 Previous Clinical Trials

63,132 Total Patients Enrolled

Rutgers Cancer Institute of New JerseyOTHER

70 Previous Clinical Trials

17,657 Total Patients Enrolled

Media Library

Ancillary-Correlative (genomic analysis) Clinical Trial Eligibility Overview. Trial Name: NCT02688517 — N/A

Cancer Research Study Groups: Ancillary-Correlative (genomic analysis)

Cancer Clinical Trial 2023: Ancillary-Correlative (genomic analysis) Highlights & Side Effects. Trial Name: NCT02688517 — N/A

Ancillary-Correlative (genomic analysis) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02688517 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment recruiting participants presently?

"Correct. Online records on clinicaltrials.gov attest that this medical investigation, which was originally posted in February 2013, is currently accepting volunteers. Approximately 1,100 patients have to be recruited from 2 distinct health centres."

Answered by AI

What is the highest capacity of participants involved in this clinical trial?

"That is correct. Data provided on clinicaltrials.gov affirms that this medical exploration, which was initially posted on February 1st 2013, is actively recruiting participants at the present time. Approximately 1100 individuals need to be recruited across two different locations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

Shridar Ganesan, MD, PhD 2013. "Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02688517.